Astellas Pharma, Inc. has hauled back its core revenue and profit guidance for the fiscal year ending next 31 March, citing the impact of the coronavirus pandemic on various aspects of its business, although its mainstay cancer product and other oncology operations remained strong.
Addressing a results briefing for the fiscal first quarter ended 30 June, chief financial officer Naoki Okamura said “the first quarter was significantly affected by COVID-19” including by pandemic-related inventory...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?